Skip to content
CNS Clinical Research

New Mexico

CNS clinical trials in New Mexico

19 CNS studies are recruiting participants at sites in 2 cities across New Mexico as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every New Mexico city with a recruiting study

By research area: Depression (7), Parkinson's Disease (6), Multiple Sclerosis (3), Migraine (2), Epilepsy (1).

Albuquerque (18), Shiprock (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in New Mexico

Basic details from each study's public record (the 12 most recently updated of 19). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Recruiting in
    Albuquerque
    Registry record
    NCT07002034 · updated
  2. Study of ALTO-300 in MDD

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Recruiting in
    Albuquerque
    Registry record
    NCT05922878 · updated
  3. Family Spirit Strengths

    • No phase
    • Ages 14 and older
    • Female participants
    Sponsor
    Johns Hopkins Bloomberg School of Public Health
    Recruiting in
    Shiprock
    Registry record
    NCT05836090 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in New Mexico on ClinicalTrials.gov.

Parkinson's disease: recently updated in New Mexico

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Albuquerque
    Registry record
    NCT06841354 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Albuquerque
    Registry record
    NCT06952504 · updated
  3. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Albuquerque
    Registry record
    NCT07174310 · updated
  4. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Recruiting in
    Albuquerque
    Registry record
    NCT06680830 · updated
  5. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Recruiting in
    Albuquerque
    Registry record
    NCT07432958 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in New Mexico on ClinicalTrials.gov.

Multiple sclerosis (MS): recently updated in New Mexico

  1. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Recruiting in
    Albuquerque
    Registry record
    NCT07299019 · updated
  2. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Recruiting in
    Albuquerque
    Registry record
    NCT06846281 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in New Mexico on ClinicalTrials.gov.

Migraine: recently updated in New Mexico

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Recruiting in
    Albuquerque
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Recruiting in
    Albuquerque
    Registry record
    NCT07674654 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in New Mexico on ClinicalTrials.gov.

Ask about studies in New Mexico

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call